Key points from article :
Juvenescence and the Buck Institute for Research on Aging announced a joint venture with the formation of Selah Therapeutics Ltd.
Focus on developing first-in-class novel ketone-based therapies for chronic diseases of aging with first priority in heart disease.
Based on research conducted on ketones in the labs of Eric Verdin, John Newman, and Brianna Stubbs at the Buck.
Ketosis is a natural metabolic state that has mechanisms directly impacting hallmarks of aging.
“Selah’s mission is focused on developing and commercializing products that have strong scientific evidence-" says Jeff Madwed, Executive Director of Juvenescence’s JuvTherapeutics Division.
Global keto market is expected to rise to $14.75 billion by 2027.
It’s not just about losing weight, as this new company plans to demonstrate.
Eric Verdin, Buck President and CEO says the new venture will be able to bring an important new therapeutic option to cardiovascular patients.
